AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00643539
Drug: Zithromax
RxNorm normalized name: Zithromax
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
Trial: NCT00643539
Drug: Clamoxyl
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
Trial: NCT00676039
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
Trial: NCT00676039
Drug: Gen-Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gen-Citalopram 40 mg (Genpharm, Generic)
Trial: NCT00676039
Drug: Effexor XR
RxNorm normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
Trial: NCT00676039
Drug: Celexa
RxNorm normalized name: Celexa
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celexa 40 mg (Lundbeck, Brand Name)
Trial: NCT00745030
Drug: Rozerem
RxNorm normalized name: Rozerem
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
Trial: NCT01614457
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
Trial: NCT01623466
Drug: levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: transdermal contraceptive delivery system
Trial: NCT00332657
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 0.5 mL injection into the PJD at 6-month intervals for 42 months
Trial: NCT00332657
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 0.5 mL injection into the PJD at 6-month intervals for 42 months
Trial: NCT02786537
Drug: PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)
RxNorm normalized name: dasabuvir / ombitasvir / paritaprevir / ritonavir
DrugBank: Carisoprodol (DB00395)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
Trial: NCT02786537
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg pills (1-3 pills, 1-2 times per day)
Trial: NCT01805115
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Trial: NCT01805115
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Trial: NCT01805115
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Trial: NCT01805115
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group was not given any cervical priming agents or placebo.
Trial: NCT03177252
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -2% lidocaine will be given
Trial: NCT03177252
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Normal saline will be given
Trial: NCT03177252
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -0.5% bupivacaine will be given
Trial: NCT04359953
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 2 x per day during 14 days
Trial: NCT04359953
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 2 x per day during 14 days
Trial: NCT01728259
Drug: pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01728259
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01728259
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03060577
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Trial: NCT03060577
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
Trial: NCT00249262
Drug: Taxoprexin
RxNorm normalized name: Talotrexin
DrugBank: Talotrexin (DB06178)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01411410
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted.
Trial: NCT01411410
Drug: Copanlisib (BAY80-6946)
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
Trial: NCT00003881
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003881
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005963
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005963
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00643045
Drug: Safinamide
RxNorm normalized name: Safinamide
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02721004
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
Trial: NCT03016715
Drug: Sirolimus 2%
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00304590
Drug: XL999
RxNorm normalized name: XL999
DrugBank: XL999 (DB05014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
Trial: NCT03133897
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: experimental group will receive 2 day treatment
Trial: NCT03133897
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control group will receive 4 day treatment
Trial: NCT01057264
Drug: HAI Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
Trial: NCT01057264
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
Trial: NCT01057264
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg IV on Day 1 of 21 day cycle
Trial: NCT01057264
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
Trial: NCT02041429
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00450463
Drug: Sargramostim (GM-CSF, Leukine)
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
Trial: NCT00450463
Drug: Flutamide (Eulexin)
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
Trial: NCT00072722
Drug: CC-4047
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00573131
Drug: OncoGel (Paclitaxel gel)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
Trial: NCT00573131
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 IV (in the vein) once on Day 1 and Day 29
Trial: NCT02041429
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00573131
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
Trial: NCT01095484
Drug: Rotigotine patch
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
Trial: NCT03033108
Drug: Emixustat
RxNorm normalized name: Emixustat
DrugBank: Emixustat (DB12608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, tablet for oral administration
Trial: NCT01506791
Drug: Desloratadine and pseudoephedrine
RxNorm normalized name: Desloratadine and pseudoephedrine only product
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine and pseudoephedrine 5/240 mg
Trial: NCT00622934
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg/kg erythropoietin 3 times on the first week of admission
Trial: NCT02556086
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02556086
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01845025
Drug: Formoterol 12 mcg
RxNorm normalized name: formoterol 12 mcg inhalation capsule
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
Trial: NCT01845025
Drug: Fluticasone propionate 100 mcg
RxNorm normalized name: fluticasone propionate 100 MCG/ACTUAT Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
Trial: NCT01845025
Drug: Fluticasone propionate 250 mcg
RxNorm normalized name: fluticasone propionate 250 MCG/ACTUAT Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
Trial: NCT01845025
Drug: Fluticasone propionate 500 mcg
RxNorm normalized name: fluticasone propionate 500 MCG / salmeterol 50 MCG (salmeterol xinafoate 72.5 MCG) per ACTUAT Metered Dose Inhaler
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
Trial: NCT03767738
Drug: Intravitreal Aflibercept Injection (IAI)
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IAI prepared and administered with a pre-filled syringe (PFS)
Trial: NCT01309425
Drug: tapentadol (CG5503) ER two 100-mg TRF
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg TRF single oral dose
Trial: NCT01309425
Drug: tapentadol (CG5503) ER 50-mg TRF
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg TRF single oral dose
Trial: NCT01309425
Drug: tapentadol (CG5503) ER 25-mg TRF
RxNorm normalized name: Tapentadol Extended-Release Tablets
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg TRF single oral dose
Trial: NCT01309425
Drug: tapentadol (CG5503) ER 100-mg TRF
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg TRF single oral dose
Trial: NCT01258205
Drug: AMG 139
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
Trial: NCT04102501
Drug: RT001
RxNorm normalized name: Risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
Trial: NCT01427712
Drug: Pancrelipase
RxNorm normalized name: pancrelipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00059475
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
Trial: NCT04250805
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
Trial: NCT04250805
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
Trial: NCT01837082
Drug: ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00059475
Drug: Montanide ISA 51
RxNorm normalized name: Montanide ISA 51
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02338362
Drug: Fluticasone propionate inhaler
RxNorm normalized name: fluticasone propionate Inhalant Product
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fluticasone propionate 250 µg metered-dose inhaler
Trial: NCT02426632
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.
Trial: NCT02426632
Drug: Formulation E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
Trial: NCT02426632
Drug: Formulation F
RxNorm normalized name: Yellow fever vaccine live - alternative formulation for vaccine shortage
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
Trial: NCT01669343
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
Trial: NCT00003820
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Trial: NCT02975323
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
Trial: NCT02297217
Drug: Carboplatin and Taxol (paclitaxel)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
Trial: NCT04509700
Drug: Parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
Trial: NCT04509700
Drug: parsaclisib + itacitinib
RxNorm normalized name: Parsaclisib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
Trial: NCT04509700
Drug: parsaclisib + ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
Trial: NCT04509700
Drug: parsaclisib + ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.